These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 28583910)

  • 1. Dramatic Responses Seen with TRK Inhibitor.
    Cancer Discov; 2017 Aug; 7(8):787. PubMed ID: 28583910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
    Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
    Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer.
    Federman N; McDermott R
    Expert Rev Clin Pharmacol; 2019 Oct; 12(10):931-939. PubMed ID: 31469968
    [No Abstract]   [Full Text] [Related]  

  • 4. The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer.
    Roth JA; Carlson JJ; Xia F; Williamson T; Sullivan SD
    J Manag Care Spec Pharm; 2020 Aug; 26(8):981-986. PubMed ID: 32329651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.
    Yang JCH; Brose MS; Castro G; Kim ES; Lassen UN; Leyvraz S; Pappo A; López-Ríos F; Reeves JA; Fellous M; Penault-Llorca F; Rudzinski ER; Tabatabai G; Vassal G; Drilon A; Trent J
    BMC Cancer; 2022 Jun; 22(1):625. PubMed ID: 35672677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to TRK inhibition mediated by convergent MAPK pathway activation.
    Cocco E; Schram AM; Kulick A; Misale S; Won HH; Yaeger R; Razavi P; Ptashkin R; Hechtman JF; Toska E; Cownie J; Somwar R; Shifman S; Mattar M; Selçuklu SD; Samoila A; Guzman S; Tuch BB; Ebata K; de Stanchina E; Nagy RJ; Lanman RB; Houck-Loomis B; Patel JA; Berger MF; Ladanyi M; Hyman DM; Drilon A; Scaltriti M
    Nat Med; 2019 Sep; 25(9):1422-1427. PubMed ID: 31406350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving outcomes in pediatric NTRK gene fusion-positive solid tumors: importance of genomic testing and targeted therapy with the TRK inhibitor larotrectinib.
    Laetsch TW
    Clin Adv Hematol Oncol; 2024 May; 22 Suppl 3(4):1-11. PubMed ID: 38739704
    [No Abstract]   [Full Text] [Related]  

  • 8. Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion.
    O'Reilly EM; Hechtman JF
    Ann Oncol; 2019 Nov; 30(Suppl_8):viii36-viii40. PubMed ID: 31605106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loxo TRK inhibitor data wows oncologists.
    Dolgin E
    Nat Biotechnol; 2017 Aug; 35(8):694-695. PubMed ID: 28787403
    [No Abstract]   [Full Text] [Related]  

  • 10. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas.
    DuBois SG; Laetsch TW; Federman N; Turpin BK; Albert CM; Nagasubramanian R; Anderson ME; Davis JL; Qamoos HE; Reynolds ME; Cruickshank S; Cox MC; Hawkins DS; Mascarenhas L; Pappo AS
    Cancer; 2018 Nov; 124(21):4241-4247. PubMed ID: 30204247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case report.
    Zhang L; Liu H; Tian Y; Wang H; Yang X
    BMC Pulm Med; 2021 Apr; 21(1):125. PubMed ID: 33865348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers.
    Farago AF; Demetri GD
    Future Oncol; 2020 Mar; 16(9):417-425. PubMed ID: 32129093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Drug approval : entrectinib and larotrectinib - cancers with NTRK fusion].
    Delaye M; Rodrigues M
    Bull Cancer; 2020 Nov; 107(11):1085-1086. PubMed ID: 33169692
    [No Abstract]   [Full Text] [Related]  

  • 14. A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.
    Drilon A; Nagasubramanian R; Blake JF; Ku N; Tuch BB; Ebata K; Smith S; Lauriault V; Kolakowski GR; Brandhuber BJ; Larsen PD; Bouhana KS; Winski SL; Hamor R; Wu WI; Parker A; Morales TH; Sullivan FX; DeWolf WE; Wollenberg LA; Gordon PR; Douglas-Lindsay DN; Scaltriti M; Benayed R; Raj S; Hanusch B; Schram AM; Jonsson P; Berger MF; Hechtman JF; Taylor BS; Andrews S; Rothenberg SM; Hyman DM
    Cancer Discov; 2017 Sep; 7(9):963-972. PubMed ID: 28578312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRK Inhibitors: Clinical Development of Larotrectinib.
    Bhangoo MS; Sigal D
    Curr Oncol Rep; 2019 Feb; 21(2):14. PubMed ID: 30715603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma.
    Waguespack SG; Drilon A; Lin JJ; Brose MS; McDermott R; Almubarak M; Bauman J; Casanova M; Krishnamurthy A; Kummar S; Leyvraz S; Oh DY; Park K; Sohal D; Sherman E; Norenberg R; Silvertown JD; Brega N; Hong DS; Cabanillas ME
    Eur J Endocrinol; 2022 Apr; 186(6):631-643. PubMed ID: 35333737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology.
    Rohrberg KS; Lassen U
    Drugs; 2021 Mar; 81(4):445-452. PubMed ID: 33400240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On the right TRK: from oncogene discovery to cancer therapeutics.
    Barbacid M
    Ann Oncol; 2019 Nov; 30 Suppl 8(Suppl 8):viii3-viii4. PubMed ID: 32223936
    [No Abstract]   [Full Text] [Related]  

  • 19. Larotrectinib for the treatment of TRK fusion solid tumors.
    Laetsch TW; Hawkins DS
    Expert Rev Anticancer Ther; 2019 Jan; 19(1):1-10. PubMed ID: 30350734
    [No Abstract]   [Full Text] [Related]  

  • 20. TRK inhibitors in TRK fusion-positive cancers.
    Drilon A
    Ann Oncol; 2019 Nov; 30 Suppl 8():viii23-viii30. PubMed ID: 32223935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.